Homocysteine, a risk factor for cardiovascular disease

International Journal of Angiology

Volumn 8, Issue 1, 1999, Pages 76-86

  Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; ENDOTHELIUM CELL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY DISEASE; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

EID: 0032953385     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01616850     Document Type: Review

References (172)

1. 1. Saikku P (1997) Chlamydia pneumoniae and atherosclerosis - an update. Scand J Infect Dis Suppl 104:53-56.
2. 2. Jackson LA, Camphell LA, Schmidt RA, et al (1997) Specificity of detection of chlamydia pneumoniae in vascular atheroma: Evaluation of the innocent bystander hypothesis. Am J Pathol 150:1785-1790.
3. 3. Selhub J, Jacques PF, Bostom AG, et al (1995) Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 332:328-329.
4. 4. Malinow MR, Nieto FJ, Szklo M, et al (1993) Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults - The atherosclerosis risk in communities study. Circulation 87:1107-1113.
5. 5. Spillmann M, Fava M (1996) S-adenosyl-methionine (ademetionine) in psychiatric disorders: historical perspectives and current status. CNS Drugs 6:416-425.
6. 6. Ubbink JB (1995) Homocysteine - an atherogenic and a thrombogenic factor? Nutr Rev 53:323-325.
7. 7. Steegers-Theunissen RPM, Boers GHJ, Blom HJ, et al (1992) Hyperhomocysteinemia and recurrent spontaneous abortion or abruptio placentae. Lancet 339:1122-1123.
8. 8. Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM, et al (1994) Maternal hyperhomocysteinemia: a risk factor for neural tube defects? Metabolism 43:1475-1480.
9. 12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci 52:M76-M79.
10. 10. Perry IJ, Refsum H, Morris RW, et al (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 345:1395-1398.
11. 11. Ueland PM, Refsum H (1989) Review article: plasma homocysteine, a risk factor for vascular disease, plasma levels in health, disease, and drug therapy. J Lab Clin Med 114:473-501.
12. 12. Boushey CJ, Beresford SAA, Omenn GS, et al (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assn 274:1049-1057.
13. 13. Finkelstein JD (1990) Methionine metabolism in mammals. J Nutr Biochem 1:228-237.
14. 14. Ueland PM, Refsum H, Stabler SP, et al (1993) Total homocysteine in plasma or serum: Methods and clinical application. Clin Chem 39:1764-1779.
15. 15. Engberson AMT, Franken DG, Boers GHJ, et al (1995) Thermolabile 5, 10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 56:142-150.
16. 16. Kang S-S, Wong PWK, Zhou J, et al (1988) Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 37:611-613.
17. 17. Kang S-S, Wong PWK, Norusis M (1987) Homocysteinemia due to folate deficiency. Metabolism 36:458-462.
18. 18. Finkelstein JD, Martin JJ, Harris BJ (1988) Methionine metabolism in mammals: the methionine-sparing effect of cystine. J Biol Chem 263:11750-11754.
19. 19. Kang S-S, Wong, PWK, Cook HY, et al (1986) Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest 77:1482-1486.
20. 20. Kang S-S, Wong PWK, Malinow MR (1992) Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 12:279-298.
21. 21. Nygärd O, Refsum H, Ueland PM, et al (1998) Major life style determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 67:263-270.
22. 22. Mudd SH, Levy HL, Skovby F (1995) Disorders of transsufuration. In: The Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, et al (eds). McGraw-Hill: New York, pp 1279-1327.
23. 23. Ballal RS, Jacobsen DW, Robinson K (1997) Homocysteine: Update on a new risk factor. Cleveland Clin J Med 64:543-549.
24. 6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 55:1154-1160.
25. 12) and folate deficiency. FASEB J 7:1344-1353.
26. 26. Refsum H, Ueland PM (1990) Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci 11:411-416.
27. 27. Ermens AAM, Refsum H, Rupreht J, et al (1991) Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocysteine and folate in plasma and urine. Clin Pharmacol Ther 49:385-393.
28. 28. Slavik M, Smith KJ, Blanc O (1982) Decrease of serum pyridoxal phosphate levels and homocysteinemia after administration of 6-azauridine triacetate and their prevention by administration of pyridoxine. Biochem Pharmacol 31:4098-4092.
29. 29. Epstein FH (1998) Homocysteine and atherosclerosis. N Engl J Med 338:1042-1048.
30. 30. Allain P, LeBouil A, Cordillet E, et al (1995) Sulphate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 16:527-529.
31. 31. Blankenhorn DH, Malinow MR, Mack WJ (1991) Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Art Dis 2:357-360.
32. 32. Robinson K, Gupta A, Dennis V, et al (1996) Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748.
33. 33. Mayer EM, Jacobsen DW, Robinson K (1996) Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 27:517-527.
34. 34. Mudd SH, Skovby F, Levy HL, et al (1985) The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 37:1-31.
35. 35. Nedrebo BG, Ericsson UB, Nygard O, et al (1998) Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 47:89-93.
36. 36. Kang S-S, Zhou J, Wong PWK, et al (1988) Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43:414-421.
37. 37. Lussier-Cacan S, Xhignesse M, Piolot A, et al (1996) Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits. Am J Clin Nutr 64:587-593.
38. 38. Wouters MGAJ, Moorrees MTEC, van der Mooren MJ, et al (1995) Plasma homocysteine and menopausal status. Eur J Clin Invest 25:801-805.
39. 39. Selhub J, Jacques PF, Wilson PWF, et al (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270:2693-2698.
40. 40. Nygärd O, Refsum H, Nordrehaug J, et al (1997) Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr 65:136-143.
41. 41. Nygärd O, Vallset SE, Refsum H, et al (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274;1526-1533.
42. 6 status. Am J Clin Nutr 63:220-224.
43. 43. Savage DG, Lindenbaum J, Stabler SP, et al (1994) Sensitivity of serum methylmalonic acid and total homocysteine determinants for diagnosing cobalamin and folate deficiencies. Am J Med 96:239-246.
44. 6 status on homocysteine metabolism. J Clin Invest 98:177-184.
45. 45. Tsai J-C, Perrella MA, Yoshizumi M, et al (1994) Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 91:6369-6373.
46. 46. Tsai J-C, Wang H, Perrella MA, et al (1996) Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 97:146-153.
47. 47. Lubec B, Labudova O, Hoeger H, et al (1996) Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 94:2620-2625.
48. 48. Graeber JE, Slott JH, Ulane RE, et al ( 1982) Effect of homocysteine and homocystine on platelet und vascular arachidonic acid metabolism. Pediatric Res 16:490-493.
49. 49. Harpel PC, Chang VT, Borth W (1992) Homocysteine and other sulfhydryl compounds enhances the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89:10193-10197.
50. 50. Rodgers GM, Kane WH ( 1986) Activation of endogenous factor V by a homocystein-induced vascular endothelial cell activator. J Clin Invest 77:1909-1016.
51. 51. Lenz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein-C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906-1914.
52. 52. Hayashi T, Honda G, Suzuki K (1992) An atherogenic stimulus homocystine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umblical vein endothelial cells. Blood 79:2930-2936.
53. 53. Nishinaga M, Ozawa T, Shimada K (1993) Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92:1381-1386.
54. 54. Hajjar KA (1993) Homocysteine-induced modulation of tissue plasmogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91:2873-2879.
55. 55. Ratnoff OD (1968) Activation of Hgeman factor by L-homocysteine. Science 162:1007-1009.
56. 56. Berman RS, Martin W (1993) Arterial endothelial barrier dysfunction: Actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Brit J Pharmacol 108:920-926.
57. 57. Lentz SR, Sadler JE (1993) Homocysteine inhibits von Willebrand Factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 81:683-689.
58. 58. Blundell G, Jones BG, Rose FA, et al (1996) Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 122:163-172.
59. 59. Jones BG, Rose FA, Tudball N (1994) Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 105:165-170.
60. 60. Harker LA, ROSS R, Slichter SJ, et al (1976) Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58:731-741.
61. 61. Lenz SR, Sobey CG, Piegors DJ, et al (1996) Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98:24-29.
62. 62. Freiman PC, Mitchell GG, Heistad DD, et al (1986) Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 58:783-789.
63. 63. Ludmer PL, Selwyn AP, Shook TL, et al (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046-1051.
64. 64. Lenz SR, Malinow MR, Piegors DJ, et al (1997) Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arter Thromb Vasc Biol 17:2930-2934.
65. 65. Loscalzo J (1996) The oxidant stress of homocyst(e)inemia. J Clin Invest 98:5-7.
66. 66. Tawakol A, Omland T, Gerhard M, et al. (1997) Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95:1119-1121.
67. 67. Ross R (1986) The pathogenesis of atherosclerosis - an update. N Engl J Med 314:488-500.
68. 68. Wall RT, Harlan JM, Harker LA, et al (1980) Homocystein-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 18:113-121.
69. 69. Harker LA, Slichter SJ, Scott CR, et al (1974) Homocysteinemia. Vascular injury and arterial thrombosis. N Engl J Med 291:537-543.
70. 70. Starkebaum G, Harlan JM (1986) Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77:1370-1376.
71. 71. Weimann BJ, Kuhn H, Baumgartner HR (1980) Effect of homocysteine on cultured bovine and human endothelial cells. Experimentia 36:762.
72. 72. Weiss SJ, Young J, LoBuglio AF, et al (1981) Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. J Clin Invest 68:714-721.
73. 73. Sacks T, Moldow CF, Craddock PR, et al (1978) Oxygen radical mediates endothelial cell damage by complement-stimulated granulocytes: an in vitro model of immune vascular damage. J Clin Invest 61:1161-1167.
74. 74. Crapo JD (1986) Morphological changes in pulmonary oxygen toxicity. Annu Rev Physiol 48:721-731.
75. 75. Olszewski AJ, McCully KS (1993) Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Raclica Biol Med 14:683-693.
76. 76. Stamler JS, Osborne JA, Jaraki O, et al (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308-318.
77. 77. Welch GN, Upchurch GR, Keaney JF, et al (1996) Homocyst(e)ine decreases cell redox potential in vascular smooth muscle cells. J Am Coll Cardiol 27(SupplA):163A (abstract).
78. 78. Hultberg B, Andersson A, Isaksson A (1995) Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture line (human histiocytic cell line). Biochem Biophys Acta 1269:6-12.
79. 79. Velury S, Howell SB (1988) Measurement of plasma thiols after derivitization with monobromobimane. J Chromatogr 424:141-146.
80. 80. Anderson A, Lindgren A, Hultberg B (1995) Effects of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 41:361-366.
81. 81. Misra HP (1974) Generation of superoxide free radical during autooxidation of thiols. J Biol Chem 249:2151-2155.
82. 82. Rowley DA, Halliwell B (1982) Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett 138:33-36.
83. 83. Heinecke JA, Rosen H, Suzuki LA, et al (1984) Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 74:1890-1894.
84. 84. Heinecke JA, Rosen H, Suzuki LA (1987) The role of sulfur-containing amino acids in Superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:98-103.
85. 85. Parthasarathy S (1987) Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL-receptor. Biochem Biophys Acta 917:337-340.
86. 86. Harker LA, Harlan JM, Ross R (1983) Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 53:731-739.
87. 87. Toborek M, Kopieczna-Grzebieniak E, Dródz M, et al (1995) Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis 115:217-224.
88. 88. Steinberg D (1991) Antioxidant and atherosclerosis: A current assessment. Circulation 84:1420-1425.
89. 89. Prasad K, Kalra J (1993) Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of Vitamin E. Am Heart J 125:958-973.
90. 90. Prasad K, Kalra J, Lee P (1994) Oxygen free radicals as a mechanism of hypercholesterolemic atherosclerosis: Effects of probucol. Internatl J Angiol 3:100-112.
91. 91. Prasad K, Mantha SV, Kalra J, et al (1997) Prevention of hypercholesterolemic atherosclerosis by garlic, an antioxidant. J Cardiovasc Pharmacol Therapeut 2:239-242.
92. 92. Prasad K, Mantha SV, Muir AD, Westcott ND (1998) Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alphalinolenic acid. Atherosclerosis 136:367-375.
93. 93. Stamler JS, Simon DI, Osborne JA, et al (1992) S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 89:444-448.
94. 94. Stamler JS, Slivka A (1996) Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 54:1-30.
95. 95. Blom HJ, Kleinveld HA, Boers GH, et al (1995) Lipid peroxidation and susceptibility of low density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 25:149-154.
96. 96. Chin JH, Azhar S, Hoffman BB (1992) Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 89:10-18.
97. 97. Liao JK, Shin WS, Lee WY, et al (1995) Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270:319-324.
98. 98. Upchurch GR Jr, Welch GN, Fabian AJ, et al (1997) Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272:17012-17017.
99. 99. Naruszewicz M, Mirkiewicz E, Olszewski AJ, et al (1994) Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 4:70-77.
100. 100. McCully KS (1993) Chemical pathology of homocysteine. I. Atherogenesis. Ann Clin Lab Sci 23:477-493.
101. 101. McCully KS (1994) Chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactate metabolism. Ann Clin Lab Sci 24:27-59.
102. 102. Poddar R, Sivasubramanian N, Robinson K, et al (1997) Homocysteine modulates the expression of a specific cytokine (monocyte chemoattractant protein-1) in human aortic endothelial cells. (Suppl.) Circulation 96:286.
103. 103. Tsai J-C, Perrell MA, Yoshizumi M, et al (1994) Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 91:6369-6373.
104. 104. Lentz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by thrombogenic agent homocysteine. J Clin Invest 88:1906-1914.
105. 105. McCully KS (1983) Homocysteine theory of atherosclerosis. Development and current status. Atheroscler Rev 11:157-246.
106. 106. McCully KS, Wilson RB (1975) Homocysteine theory of arteriosclerosis. Atherosclerosis 22:215-227.
107. 107. McCully KS, Ragsdale BD (1970) Production of arteriosclerosis by homocysteinemia. Am J Pathol 61:1-11.
108. 108. McCully KS (1972) Homocysteinemia and arteriosclerosis. Am Heart J 83:571-573.
109. 109. McCully KS, Olszewski AJ, Vezeridis MP (1990) Homocysteine and lipid metabolism in atherogenesis: effect of the homocysteine thiolactonyl derivatives, thioretinaco and thioretinamide. Atherosclerosis 83:197-206.
110. 110. McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis for atherosclerosis. Am J Pathol 56: 111-128.
111. 111. Fau D, Peret J, Hadjiisky P (1988) Effects of ingestion of high protein or excess methionine diets by rats for two years. J Nutr 118:128-133.
112. 112. Hladovec J (1980) Experimental homocysteinemia, endothelial lesions and thrombosis. Blood Vessels 16:202-205.
113. 113. Matthias D, Becker CH, Riezler R, et al (1996) Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 122:201-216.
114. 114. Reddy OS, Wilcken DE (1982) Experimental homocysteinemia in pigs; comparison with studies in sixteen homocysteinuric patients. Metabolism 31:778-783.
115. 115. Krishnaswamy K, Rao SB (1977) Failure to produce atherosclerosis in Macaca radiata on a high methionine, high fat, pyridoxine deficient diet. Atherosclerosis 27:253-258.
116. 116. Koyama J (1995) The influence of methionine and its metabolites on the progression of atherosclerosis in rabbits. Nippon Ika Daigaku Zasshi 62:596-604.
117. 117. Wilcken DEL, Wilcken B (1976) The pathogenesis of coronary artery disease. A possible role of methionine metabolism. J Clin Invest 57:1079-1082.
118. 118. Israelsson B, Brattström LE, Hultberg BJ (1988) Homocysteine and myocardial infarction. Atherosclerosis 71:227-234.
119. 119. Clarke R, Daly L, Robinson K, et al (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149-1155.
120. 120. Coull BM, Malinow MR, Beamer N, et al (1990) Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 21:572-576.
121. 121. Stampfer MJ, Malinow MR, Willett WC, et al (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assn 268:877-881.
122. 6. Res Commun Mol Pathol Pharmacol 89:208-220.
123. 123. Frohlich JJ (1995) Lipoproteins and homocysteine as risk factors for atherosclerosis: assessment and treatment. Canad J Cardiol 11(Suppl C):18C-23C.
124. 124. Glueck CJ, Shaw P, Lang JE, et al (1995) Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 75:132-136.
125. 125. Stampfer MJ, Malinow MR (1995) Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 332:328-329.
126. 126. Arnesen S, Refsum H, Bonaa KH, et al (1995) Serum total homocysteine and coronary artery disease. Int J Epidemiol 24:704-709.
127. 127. Taylor LM, DeFrang RD, Harris EJ, et al (1991) The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13:128-136.
128. 128. Alfthan G, Pekkanen J, Jauhiainen M, et al (1994) Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in prospective Finnish population based study. Atherosclerosis 106:9-19.
129. 129. Nygárd O, Nordrehaug JE, Refsum H, et al (1997) Plasma homocysleine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236.
130. 130. Fortin LJ, Genest J Jr (1995) Measurement of homocysteine in the prediction of arteriosclerosis. Clin Biochem 28:155-162.
131. 131. Verhoef P, Hennekens CH, Malinow MR, et al (1994) A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 25:1924-1930.
132. 132. Hoogeveen EK, Kostense PJ, Beks PJ, et al (1998) Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in noninsulin-dependent diabetes mellitus. A population-based study. Arterioscl Thromb Vasc Biol 18:133-138.
133. 133. Bots ML, Launer LJ, Lindemans J, et al (1997) Homocysteine, atherosclerosis and prevalent cardiovascular disease in elderly: The Rotterdam study. J Internal Med 242:339-347.
134. 134. Van-den-Berg M, Stehouwer CD, Bierdrager E, et al (1996) Plasma homocysteine and severity of atherosclerosis in young patients with lower limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 16:165-171.
135. 135. Berger PB, Jones JD, Olson U, et al (1995) Increase in total plasma homocysteine concentration after cardiac transplantation. Mayo Clin Proc 70:125-131.
136. 136. Malinow MR (1994) Homocysteine and arterial occlusive diseases. J Intern Med 236:603-617.
137. 137. Willinek WA, Lennarz M, Dudek M, et al (1997) High normal serum homocysteine concentrations are associated with an increased risk for early atherosclerotic carotid artery wall lesions in normotensive subjects. Proceedings 4th Symposium on "Multiple Risk Factors in Cardiovascular Disease: Strategies of Prevention of Coronary Heart Disease, Cardiac Failure, and Stroke". Washington DC p. 39 (Abstract).
138. 138. Boers GHJ, Smals AGH, Trijbels FJM, et al ( 1985) Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313:709-715.
139. 139. den Heijer M, Kostor T, Blom HJ, et al (1996) Homocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762.
140. 140. den Heijer M, Blom HJ, Gerrits WBJ, et al (1995) Is hyperchomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 345:882-885.
141. 141. Ridker PM, Hennekens CH, Selhub J, et al (1997) Interralation of hyperhomocysteinemia, factor V Lieden and risk of future venous thromboembolism. Circulation 95:1777-1782.
142. 142. Brattström L, Tengborn L, Israelsson B, et al (1991) Plasma homocysteine in venous thromboembolism. Haemostasis 21:51-57.
143. 143. Bienvenu T, Ankri A, Chadefaux B, et al (1991) Plasma homocysteine assay in the exploration of thrombosis in young subjects. Presse Médicale 20:985-988.
144. 144. Bostom AG, Brosnan JT, Hall B, et al (1995) Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116:59-62.
145. 145. Holdt B, Korten G, Knippel M, et al (1996) Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Internatl 16(Suppl. 1):S246-S249.
146. 146. Bostom AG, Shemin D, Lapane KL, et al (1996) High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Intnatl 49:147-152.
147. 147. Bostom AG, Shemin D, Yoburn D, et al (1996) Lack of effect of oral N-acetylcysteine on acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 120:241-244.
148. 148. Chauveau P, Chadefaux B, Coude M, et al (1993) Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Internatl Suppl 41:S72-S77.
149. 149. Chauveau P, Chadefaux B, Conde M, et al (1996) Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 22:106-109.
150. 150. Munshi MN, Stone A, Fink L, et al (1996) Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 45:133-135.
151. 151. Araki A, Sako Y, Ito H (1993) Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: Effect of parenteral methylcobalamin treatment. Atherosclerosis 103:149-157.
152. 152. Agardh CD, Agardh E, Andersson A, et al (1994) Lack of association between plasma homocysteine levels and microangiopathy in Type I diabetes mellitus. Scand J Clin Lab Invest 54:637-641.
153. 153. Robillon JF, Canivet B, Candito M, et al (1994) Type I diabetes mellitus and homocysteine. Diabet Metab 20:494-496.
154. 12 concentrations are risk for early onset coronary artery disease. Am J Clin Nutr 59:940-948.
155. 155. Tonstad S, Joakimsen O, Stenslandbugge E, et al (1996) Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Dis 16:984-991.
156. 156. Araki A, Sako Y, Fukushima Y, et al ( 1989) Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 79:139-146.
157. 157. Malinow MR, Levenson J, Giral P, et al (1995) Role of blood pressure, uric acid and hemorheological parameters on plasma homocysteine concentration. Atherosclerosis 114:175-183.
158. 158. Lolin YI, Sanderson JE, Cheng SK, et al (1996) Hyperhomocysteinemia and premature coronary artery disease in Chinese. Heart 76:117-122.
159. 159. Ma J, Stampfer MJ, Hennekens CH, et al (1996) Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94:2410-2416.
160. 160. Graham IM, Daly LE, Refsum HM, et al (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277:1775-1781.
161. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet 346:85-89.
162. 162. Abou-Gazala T, Lobo A, Alsous F, et al (1997) High plasma homocysteine, in patients with coronary artery disease, can be reduced by folic acid supplementation. J Am Coll Cardiol 27(SuppI2A):488A (Abstract).
163. 163. Brattström L (1996) Vitamins as homocysteine-lowering agents. J Nutr 126:12765-12805.
164. 6 and folic acid on mild hyperhomocysteinemia in vascular patients. J Inherit Metab Dis 17:159-162.
165. 165. Ubbink JB, Vermaak WJ, vander Merwe A, et al (1994) Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124:1927-1933.
166. 6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57:47-53.
167. 167. Landgren F, Israelsson B, Lindgren A, et al (1995) Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 237:381-388.
168. 168. Butterworth CEJ, Tamura T (1989) Folic acid safety and toxicity: a brief review. Am J Clin Nutr 50:353-358.
169. 169. Refsum H, Ueland PM, Nygárd O, et al (1998) Homocysteine and cardiovascular disease. Ann Rev Med 49:31-62.
170. 170. Brattström LE, Israelsson B, Jeppsson JO, et al (1988) Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48:215-221.
171. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 20:933-940.
172. 6 in clinical neurology. Ann NY Acad Sci 585:250-260.